UK-based Enesi Pharma and The University of Adelaide announced on September 22, 2020, that they are collaborating to accelerate the development of a novel needle-free vaccine for the Zika virus (ZIKV). This project will utilize a protective Zika virus DNA vaccine developed by the University of Adelaide, with Enesi Pharma’s ImplaVax technology.
The technology delivers a thermostable single solid dose implant containing the vaccine through the skin and into the tissue, without using a needle. Once inserted, the implant dissolves, releasing the active ingredient over time and inducing the desired immune response.
The University of Adelaide researchers will progress the pre-clinical work necessary to take the Zika vaccine to Phase 1 clinical trials. This work will be undertaken in collaboration with colleagues from the University of Wisconsin-Madison, Harvard University, and the Duke-National University of Singapore.